Asterias Financial Statements From 2010 to 2024

Asterias Biotherapeutics financial statements provide useful quarterly and yearly information to potential Asterias Biotherapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Asterias Biotherapeutics financial statements helps investors assess Asterias Biotherapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Asterias Biotherapeutics' valuation are summarized below:
Asterias Biotherapeutics does not presently have any fundamental signals for analysis.
Check Asterias Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Asterias main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Asterias financial statements analysis is a perfect complement when working with Asterias Biotherapeutics Valuation or Volatility modules.
  
This module can also supplement various Asterias Biotherapeutics Technical models . Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

Asterias Cash Flow From Operations Analysis

Asterias Biotherapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Operating Cash Flow

 = 

EBITDA

-

Taxes

More About Cash Flow From Operations | All Equity Analysis

Current Asterias Biotherapeutics Cash Flow From Operations

    
  (15.82 M)  
Most of Asterias Biotherapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Asterias Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Competition
In accordance with the recently published financial statements, Asterias Biotherapeutics has (15.82 Million) in Cash Flow From Operations. This is 103.0% lower than that of the sector and 125.3% lower than that of the Cash Flow From Operations industry. The cash flow from operations for all United States stocks is 101.63% higher than that of the company.

Asterias Biotherapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Asterias Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Asterias Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Asterias Biotherapeutics competition to find correlations between indicators driving Asterias Biotherapeutics's intrinsic value. More Info.
Asterias Biotherapeutics is rated below average in shares owned by institutions category among related companies. It is rated below average in earnings per share category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Asterias Biotherapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Asterias Biotherapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Asterias Biotherapeutics' earnings, one of the primary drivers of an investment's value.

Pair Trading with Asterias Biotherapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Asterias Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Asterias Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Allstate could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allstate when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allstate - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling The Allstate to buy it.
The correlation of Allstate is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allstate moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allstate moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allstate can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Other Consideration for investing in Asterias Stock

If you are still planning to invest in Asterias Biotherapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Asterias Biotherapeutics' history and understand the potential risks before investing.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation